Eloxx Pharmaceuticals reported second-quarter 2026 results after completing a $66.0 million underwritten public offering and moving its shares to the Nasdaq Capital Market under the ticker ELOX, steps the company said materially strengthened its balance sheet. The company ended June with $62.0 million in cash and cash equivalents and no outstanding debt, and said that funding should support operations into mid-2028, including expected data readouts for exaluren in nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease, or ADPKD. Eloxx said the U.S. Food and Drug Administration, or FDA (U.S. drug regulator), cleared its Investigational New Drug application for a Phase 2b trial of exaluren in nonsense mutation Alport syndrome, with study initiation planned in the third quarter of 2026. Topline data from the initial 16-week placebo-controlled portion are expected by mid-2027, with the final readout due by the end of 2027. In July 2026, the European Commission granted orphan medicinal product designation to exaluren for ADPKD, and the company plans to begin a Phase 2 trial in nonsense mutation ADPKD in 2027, with topline data anticipated by mid-2028. Net loss for the three months ended June 30, 2026 was $4.5 million, compared with $1.9 million a year earlier, as research and development and general and administrative costs increased. Eloxx also appointed Stephen W. Webster and Nina Kjellson to its board in May 2026 and said it remains eligible for up to about $470.0 million in development and sales milestones, plus tiered royalties, from Almirall, S.A.'s work on ZKN-013.